Press release content from Business Wire. The AP news staff was not involved in its creation.

Papulopustular Rosacea Drug Pipeline Landscape Report 2022 Featuring Key Players - Timber Pharmaceuticals, Dermata Therapeutics, CAGE Bio, Promius Pharma, Alfasigma, BioMimetix -

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
December 20, 2022 GMT

DUBLIN--(BUSINESS WIRE)--Dec 20, 2022--

The “Papulopustular Rosacea - Pipeline Insight, 2022” drug pipelines has been added to’s offering.

This “Papulopustular Rosacea- Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Papulopustular Rosacea pipeline landscape.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Papulopustular Rosacea pipeline landscape is provided which includes the disease overview and Papulopustular Rosacea treatment guidelines.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces, in depth Papulopustular Rosacea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Papulopustular Rosacea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Papulopustular Rosacea R&D. The therapies under development are focused on novel approaches to treat/improve Papulopustular Rosacea.

Papulopustular Rosacea Emerging Drugs Chapters

This segment of the Papulopustular Rosacea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Papulopustular Rosacea Emerging Drugs

DMT310: Dermata Therapeutics

DMT310 is the lead product candidate, developed from Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications.


It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties.

After processing, the sponge powder contains precisely sized and shaped silica spicules that upon application may help exfoliate the skin, promote collagen production, open closed comedones (creating an aerobic environment to help kill C. acne bacteria) and create microchannels to facilitate penetration of the sponge’s naturally occurring chemical compounds. These chemical compounds have been shown, in-vitro, to have both antimicrobial and anti-inflammatory properties, which is believed to play a significant role in the treatment of inflammatory skin diseases, such as acne.


BPX-04: Timber Pharmaceuticals

BPX-04 (minocycline), is a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.

The product has demonstrated safety and efficacy in a randomized, double-blind, vehicle-controlled Phase 2b clinical trial which enrolled 206 subjects with moderate-to-severe papulopustular rosacea. In addition to meeting the primary and secondary endpoints of the trial, BPX-04 demonstrated a statistically significant reduction in the number of facial inflammatory lesions at all-time points (weeks 4, 8 and 12).

Papulopustular Rosacea: Therapeutic Assessment


This segment of the report provides insights about the different Papulopustular Rosacea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Papulopustular Rosacea

There are approx. 20+ key companies which are developing the therapies for Papulopustular Rosacea. The companies which have their Papulopustular Rosacea drug candidates in the most advanced stage, i.e. Phase II, Timber Pharmaceuticals.

Papulopustular Rosacea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Papulopustular Rosacea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Papulopustular Rosacea drugs.

Papulopustular Rosacea Report Insights

  • Papulopustular Rosacea Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs


Papulopustular Rosacea Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Timber Pharmaceuticals
  • Dermata Therapeutics
  • CAGE Bio
  • Promius Pharma
  • Alfasigma
  • BioMimetix

Key Products

  • DMT310
  • BPX-04
  • CGB-400
  • DFD-29
  • Rifaximin
  • BMX-010

For more information about this drug pipelines report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 12/20/2022 10:48 AM/DISC: 12/20/2022 10:48 AM